secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-05-12T20:15:50+00:00
Accession:  0001104659-26-059408
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio Q3: no revenue, cash $74.8M; Phase 1 clearance for IBIO-600; IBIO-610 reduces visceral fat 6.7%
--------------------------------------------------------------------------------

- No revenue for Q3 FY2026; R&D expenses $3.3M (up $1.4M YoY); G&A $5.1M (includes $2.5M impairment of IBIO-101 intangible).
- Cash, cash equivalents, and investments in debt securities $74.8M as of March 31, 2026; additional $17M from warrant exercises in Q4, extending cash runway into Q4 FY2028.
- Received regulatory clearance from Australia's TGA and HREC to initiate Phase 1 trial of IBIO-600 (anti-myostatin antibody) in overweight/obese adults; first dosing expected Q2 calendar 2026.
- Announced pipeline expansion into PH-HFpEF with a selective bispecific antibody blocking Activin A, GDF8, GDF11 to reduce cardiac fibrosis and vascular remodeling.
- Preclinical NHP data for IBIO-610: after two doses, visceral fat reduced by 6.7%, total fat mass by 5.2% (small, not statistically powered study).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/0001104659-26-059408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926059408/ibio-20260512x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-059408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer